Comparative Pharmacology
Head-to-head clinical analysis: BENYLIN versus CYPROHEPTADINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENYLIN versus CYPROHEPTADINE HYDROCHLORIDE.
BENYLIN vs CYPROHEPTADINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BENYLIN (diphenhydramine) is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, thereby alleviating allergic symptoms. It also crosses the blood-brain barrier and acts as a central nervous system depressant via inhibition of histamine and acetylcholine, producing sedative, antiemetic, and antitussive effects.
Cyproheptadine is a potent antihistamine (H1 receptor antagonist) and antiserotonergic agent (5-HT2 receptor antagonist). It also exhibits weak anticholinergic and sedative properties. It blocks histamine-mediated vasodilation, increased capillary permeability, and pruritus, as well as serotonin-mediated effects on appetite and mood.
Oral: 10-20 mL (25-50 mg diphenhydramine) every 4-6 hours; maximum 100 mg per day.
4 mg orally three times daily; range 4-20 mg/day, not to exceed 0.5 mg/kg/day
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in adults; extended to 10-12 hours in hepatic impairment, increasing risk of accumulation.
Terminal half-life approximately 8–16 hours in adults; may be prolonged in elderly or hepatic impairment.
Renal: ~80% as unchanged drug and glucuronide conjugates; fecal/biliary: ~20%.
Primarily renal (appreciable unchanged drug and metabolites); biliary/fecal elimination minor (<5%).
Category C
Category A/B
Antihistamine
Antihistamine